The infectivity and severity of the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) pandemic (coronavirus disease 2019 [COVID-19]) has fostered the need for speed in the work to make progress against the virus.
Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Sildenafil is the active substance in Viagra® tablets, which is approved by the FDA to treat sexual dysfunction in men. Poor solubility and short half-life, however, can limit the span of its effectiveness.
Simulx Webinar: Optimizing Sample Size of a Phase III trial
What if we could reduce the size of a phase III study from 400 to 80 subjects and make it twice as short? Thanks to model-informed clinical trial design, it's possible!
Scaling Approaches for Pediatric Dose Selection: the Fremanezumab (AJOVY®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data From a Phase 1 Study. Pharmaceuticals
Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and
Pulmonary PBPK Modeling for Inhaled Products: Antibiotic Case Studies
What are we doing for inhaled products today?
NAFLDsym Application Showcase: Key Examples of NAFLDsym Use within Drug Development
NAFLDsym is a quantitative systems pharmacology (QSP) modeling software to support the development of treatments for non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Using Quantitative Systems Pharmacology Modeling to Understand the Pathophysiology of Idiopathic Pulmonary Fibrosis
Patients with idiopathic pulmonary fibrosis (IPF) have a poor survival prognosis and limited treatment options.
Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia
For treatment of chronic cancers, the oral administration route is preferred as it provides numerous advantages over other delivery routes.
Simulations Plus Uplisted to The Nasdaq Global Select Market®
Strong growth, innovation, and global reach drive the company’s progress
May 2021 GastroPlus Newsletter
We hope that you and yours are coming out of our Covid enforced isolation.
Evaluating the Hepatotoxicity of Compound V with QST/QSP Modeling
Is your compound causing drug-induced liver injury?
May 2021 News/Events
Did you know? We provide high-quality analysis & support services including non-compartmental PK analysis, population PK and PK/PD modeling, PBPK modeling in GastroPlus®, and statistical modeling, focusing on...
Applications of Pharmacometrics in Phase 1 Studies
Phase 1 is a drug development stage where you start the clinical evaluation of the drug.
Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists
Selatogrel is a potent and reversible P2Y12 receptor antagonist developed for subcutaneous self‐administration by patients with suspected acute myocardial infarction.
DILIsym® Applications in Drug Development – Perspectives from 2 Pharma Industry Executives & an Experienced Consultant
What do NURTEC™ ODT, TURALIO®, lixivaptan, solithromycin, JYNARQUE®, VEKLURI®, and UBRELVY® have in common?
Modeling and Simulation of a parent-metabolite-PD datatset (Spring School challenge solution)
Whether you have participated to our Spring School and its modeling challenge or not, this webinar is for you!